Literature DB >> 22221267

The microbiologic safety of umbilical cord blood transfusion for children with severe anemia in Mombasa, Kenya.

Oliver W Hassall1, Johnstone Thitiri, Greg Fegan, Lewa Pole, Salim Mwarumba, Douglas Denje, Kongo Wambua, Brett Lowe, Christopher M Parry, Kishor Mandaliya, Kathryn Maitland, Imelda Bates.   

Abstract

BACKGROUND: Severe anemia requiring blood transfusion is common in hospitalized young children in sub-Saharan Africa but blood is often in short supply. Umbilical cord blood may be a useful source of blood if microbiologic safety concerns can be addressed. STUDY DESIGN AND METHODS: Cord blood, donated on the labor ward at the provincial hospital in Mombasa, was cultured soon after collection (screening culture) and after a period of storage (poststorage culture). Conventional blood transfused to children at the hospital was cultured only at the time of issue (poststorage culture). Maternal sera (cord blood) and conventional blood donations were also screened for transfusion-transmitted infection.
RESULTS: At poststorage culture, the overall contamination rate of cord blood was one-third that of conventional blood (13/449 vs. 38/434; odds ratio [OR], 0.31; 95% confidence interval [CI], 0.15-0.61) and for bacteria of high pathogenic potential it was half that of conventional blood (4/449 vs. 7/434; OR, 0.55; 95% CI, 0.12-2.18). Screening cultures were positive in 50% (2/4) of cord blood packs where an organism of high pathogenic potential was isolated at poststorage culture. Cord blood donors had a lower seroreactivity than conventional donors for human immunodeficiency virus (OR, 0.63; 95% CI, 0.29-1.18), hepatitis B virus (OR, 0.32; 95% CI, 0.16-0.59), and hepatitis C virus (OR, 0.20; 95% CI, 0.24-0.76). For syphilis, initial seroreactivity in cord blood donors was 3.8% compared to 1.8% in conventional blood donors (OR, 2.10; 95% CI, 1.15-3.60) but was 0.5% after retesting.
CONCLUSION: With respect to bacterial contamination and seroreactivity for transfusion-transmitted infection, the safety of cord blood in Mombasa compares favorably with conventional blood. Clinical trials of cord blood transfusion are justified.
© 2011 American Association of Blood Banks.

Entities:  

Mesh:

Year:  2011        PMID: 22221267     DOI: 10.1111/j.1537-2995.2011.03487.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Safety and efficacy of allogeneic umbilical cord red blood cell transfusion for children with severe anaemia in a Kenyan hospital: an open-label single-arm trial.

Authors:  Oliver W Hassall; Johnstone Thitiri; Greg Fegan; Fauzat Hamid; Salim Mwarumba; Douglas Denje; Kongo Wambua; Kishor Mandaliya; Kathryn Maitland; Imelda Bates
Journal:  Lancet Haematol       Date:  2015-02-13       Impact factor: 30.153

2.  Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain.

Authors:  Paolo Rebulla; Sergio Querol; Simonetta Pupella; Daniele Prati; Joaquin Delgadillo; Vincenzo De Angelis
Journal:  Front Cell Dev Biol       Date:  2022-01-04

3.  Molecular characterization of microbial contaminants isolated from Umbilical Cord Blood Units for transplant.

Authors:  Juan Manuel Bello-López; Jorge Noguerón-Silva; Jorge Ismael Castañeda-Sánchez; Julieta Rojo-Medina
Journal:  Braz J Infect Dis       Date:  2015-09-09       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.